HK1153143A1 - Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings - Google Patents

Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings

Info

Publication number
HK1153143A1
HK1153143A1 HK11107352.4A HK11107352A HK1153143A1 HK 1153143 A1 HK1153143 A1 HK 1153143A1 HK 11107352 A HK11107352 A HK 11107352A HK 1153143 A1 HK1153143 A1 HK 1153143A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
treatment
type
pharmaceutical composition
human beings
Prior art date
Application number
HK11107352.4A
Other languages
English (en)
Inventor
Kaihong Yuan
Shuqin Ma
Huawen Liu
Yafei Zhu
Leiming Li
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HK1153143A1 publication Critical patent/HK1153143A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11107352.4A 2009-07-21 2011-07-15 Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings HK1153143A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101403973A CN101961336B (zh) 2009-07-21 2009-07-21 治疗哺乳动物包括人2型糖尿病的药物组合物

Publications (1)

Publication Number Publication Date
HK1153143A1 true HK1153143A1 (en) 2012-03-23

Family

ID=43498754

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11107352.4A HK1153143A1 (en) 2009-07-21 2011-07-15 Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings

Country Status (3)

Country Link
CN (1) CN101961336B (fr)
HK (1) HK1153143A1 (fr)
WO (1) WO2011009360A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108144065B (zh) * 2016-12-06 2023-05-16 江苏恒瑞医药股份有限公司 一种dpp-4抑制剂的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287495A (zh) * 2005-06-10 2008-10-15 诺瓦提斯公司 Dpp-iv抑制剂和格列酮的直接压片的制剂和制备方法
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2011009360A1 (fr) 2011-01-27
CN101961336B (zh) 2012-05-30
CN101961336A (zh) 2011-02-02

Similar Documents

Publication Publication Date Title
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL220684A (en) Anaphylactic therapy for Alzheimer's and the aging brain
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
HUE038785T2 (hu) Hagyományos kínai gyógyszerkészítmény szív- és érrendszeri betegségek kezelésére
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
PT2358373E (pt) Composição injetável de polidesoxirribonucleotídeos para o tratamento de doenças osteoarticulares
IL223289A (en) The history of triazine and pharmaceutical preparations containing them for the treatment of type 2 diabetes
GB0903158D0 (en) Cosmetic or pharmaceutical preparation for the skin
EP2306824A4 (fr) Administration par ionophorèse de curcumine et analogues de curcumine destinés au traitement de la maladie d'alzheimer
PT2842555T (pt) Derivados-alfa de ácidos gordos cis-monoinsaturados para uso como medicamentos no tratamento de diabetes
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
IL213703A (en) Compounds for the treatment of pain and other diseases
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
HK1156844A1 (en) Pharmaceutical composition 271 271
IL200753A (en) Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
HK1147700A1 (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including man
EP2402342A4 (fr) Composition pharmaceutique servant a traiter le diabete de type 2
PT2344166E (pt) Composição farmacêutica para o tratamento da irritação gastrointestinal
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230723